Raymond James Financial
STLN

Raymond James Financial’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Raymond James Financial’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,748
Closed -$125K – 5335
2025
Q3 		$125K Buy
35,748
+33,417
+1,434% +$114K ﹤0.01% 4715
2025
Q2 		$4.78K Buy
+2,331
New +$5.83K ﹤0.01% 6185

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's STLN Position: Q4 2025 in Review

Raymond James Financial sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 35,748 shares — an estimated $125K sold.

Raymond James Financial first reported a position in STLN in Q2 2025 and held it in 2 quarters. The position peaked at $125K in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Raymond James Financial reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 35,748 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $125K.
  • Raymond James Financial first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Starling Oncology Institute, Inc. Common Stock position peaked at $125K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.